XHKG
2112
Market cap7mUSD
Oct 09, Last price
0.04HKD
1D
0.00%
1Q
-7.14%
Jan 2017
-97.68%
IPO
-97.02%
Name
Grace Life-tech Holdings Ltd
Chart & performance
P/E
—
P/S
0.57
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-14.06%
Revenues
13m
-5.11%
Net income
-15m
L-67.93%
CFO
-373k
L+396.73%
Dividend
May 07, 20140.051 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Grace Life-tech Holdings Limited, an investment holding company, engages in the research, development, and application of plant stem cell technology. It is also involved in the provision of health solutions and product sales in Hong Kong, the People’s Republic of China, Malaysia, and internationally. It operates through Iron Ore Mining and Processing Operation, Commercial Trade, Health Products Trade, Electronic Products Trade, and Others segments. The Iron Ore Mining and Processing Operation segment engages in the mining and sale of iron ore. The Commercial Trade segment trades in crude oil and other commodities. The Health Products Trade segment trades in health products. The Electronic Products Trade segment engages in the trading of electronic devices products. The Others segment trades in other products. The company was formerly known as CAA Resources Limited and changed its name to Grace Life-tech Holdings Limited in December 2022. Grace Life-tech Holdings Limited was founded in 2007 and is based in Lai Chi Kok, Hong Kong. Grace Life-tech Holdings Limited operates as a subsidiary of Cosmo Field Holdings Limited.
Key people
Khing Yeu Ng
Executive Co-Chairman of the Board · since 2022
Xiaolan Li
Deputy General Manager, Executive Director · since 2013
Er Wang
Executive Director, Production Supervisor · since 2013
Company Secretary · since 2022
Jie Dong
Non-Executive Independent Director · since 2024
Independent Non-Executive Director · since 2022
Ling Wang
Independent Non-Executive Director · since 2013
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||